Amid the concerns surrounding potential rare side effects of the AstraZeneca-Oxford Covid-19 vaccine, the pharmaceutical ...

Cambridge [United Kingdom], May 1 (ANI): In light of recent concerns surrounding potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant has reiterated its ...

European safety regulators have launched an investigation into the safety of a batch of the Oxford University/AstraZeneca COVID-19 vaccine, as countries including Denmark suspended its use as a ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

Patient safety is our highest priority." The statement added that AstraZeneca’s vaccine “has continuously been shown to have an acceptable safety profile and regulators around the world ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

With a new hearing scheduled for November 27, 2024, questions persist regarding the safety of the vaccine ... several vaccines including AstraZeneca, Moderna, Pfizer-BioNTtech, Johnson and Johnson ...

AstraZeneca has paused its planned £450 million investment in the UK for vaccine R&D as it continues discussions with the ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

Last week, AstraZeneca reiterated its commitment to patient safety while emphasising the vaccine's overall safety profile. An AstraZeneca spokesperson had stated, "Our sympathy goes out to anyone ...